Table 1.
Baseline characteristics of eligible patients (n = 368)
| Demographic and clinical characteristics | No. (%) |
|---|---|
| Median age (range), y | 60.2 (21.1-89.3) |
| Age, y | |
| <65 | 231 (62.8) |
| ≥65 | 137 (37.2) |
| Sex | |
| Female | 140 (38.0) |
| Male | 228 (61.9) |
| Race | |
| Asian or Pacific Islander | 17 (4.6) |
| Black | 48 (13.0) |
| White | 286 (77.7) |
| Other or Unknown | 17 (4.6) |
| Marital status | |
| Married/Partnered | 213 (57.9) |
| Divorced or separated | 82 (22.2) |
| Widowed | 17 (4.6) |
| Never married | 48 (13.0) |
| Unknown | 8 (2.2) |
| Primary insurance | |
| Private insurance (employer provided) | 171 (46.5) |
| Medicare | 143 (38.9) |
| Medicaid | 44 (11.9) |
| Other | 3 (0.82) |
| Uninsured | 7 (1.9) |
| Total household income | |
| $0-$25 000 | 114 (30.9) |
| $25 001-$50 000 | 94 (25.5) |
| $50 001-$75 000 | 54 (14.7) |
| $75 001-$100 000 | 31 (8.4) |
| $100 001 or more | 65 (17.7) |
| Unknown | 10 (2.7) |
| Education | |
| High school graduate or less | 143 (38.9) |
| Vocational school or some college | 111 (30.2) |
| Bachelor degree | 63 (17.1) |
| Master, doctorate, or professional degree | 43 (11.7) |
| Missing | 8 (2.2) |
| Homeowner | |
| Yes | 236 (64.1) |
| No | 124 (33.7) |
| Unknown | 8 (2.2) |
| Prediagnosis employment status | |
| Employed (full-time, part-time, self-employed) | 222 (60.3) |
| Retired | 93 (25.3) |
| On leave of absence from paid employment | 2 (0.5) |
| Unemployed | 13 (3.5) |
| Temporary or permanent disability | 25 (6.8) |
| Other or unknown | 13 (3.5) |
| Total assets | |
| $0-$25 000 | 202 (54.9) |
| $25 001-$50 000 | 25 (6.8) |
| $50 001-$100 000 | 38 (10.3) |
| $100 001-$250 000 | 32 (8.7) |
| $250 001-$500 000 | 29 (7.9) |
| $500 001 or more | 34 (9.2) |
| Unknown | 8 (2.2) |
| Prior diagnosis of stage I-III colorectal cancer | |
| Yes | 93 (25.2) |
| No, de novo diagnosis of stage IV | 275 (74.7) |
| ECOG PS | |
| 0 | 183 (49.7) |
| 1 | 158 (42.9) |
| 2 | 22 (5.9) |
| 3 | 4 (1.1) |
| Unknown | 1 (0.3) |
| Initial treatment regimen | |
| (5-FU or cap) ± bevacizumab | 38 (10.3) |
| (FOLFOX or CapOX) ± bevacizumaba | 228 (61.9) |
| (FOLFIRI or CapIri) ± bevacizumaba | 55 (14.9) |
| (FOLFOX, CapOx, FOLFIRI, or CapIRI) + EGFR inhibitor | 15 (4.1) |
| Other | 32 (8.7) |
a
Exact proportion of patients receiving 5-FU vs capecitabine alone or in the chemotherapy backbone is not measured. 5-FU = 5-fluorouracil; Cap = capecitabine; CapIRI = capecitabine + irinotecan; CAPOX = capecitabine + oxaliplatin; ECOG PS = Eastern Cooperative Oncology Group Performance Status; FOLFIRI = regimen including 5-FU + leucovorin + irinotecan; FOLFOX = regimen including 5-FU + leucovorin + oxaliplatin.